. Mucin secretion and PKC isoforms in SPOC1 goblet cells: differential activation by purinergic agonist and PMA. Am J Physiol Lung Cell Mol Physiol 285: L149-L160, 2003. First published February 14, 2003 10.1152 10. /ajplung.00359.2002 which are a mucin-secreting model of rat airway goblet cells, possess a luminal P2Y2 purinoceptor through which UTP, ATP, and ATP␥S stimulate secretion with EC50 values of ϳ3 M. PMA elicits mucin secretion with high EC 50 (75 nM) and saturation (300 nM) values. For the first time in airway mucinsecreting cells, the PKC isoforms expressed and activated by a secretagogue were determined using RT-PCR/restrictionenzyme mapping and Western blotting. Five isoforms were expressed: cPKC␣, nPKC␦ and -, and aPKC and -/. PMA caused cPKC␣ and nPKC␦ to translocate to the membrane fraction of SPOC1 cells; only nPKC␦ so responded to ATP␥S. Membrane-associated nPKC␦ and mucin secretion increased in parallel with ATP␥S concentration and yielded EC50 values of 2-3 M and maximum values of 100 M. Effects of PMA to increase membrane-associated cPKC␣ and nPKC␦ saturated at 30 nM, whereas mucin secretion saturated at 300 nM, which suggests a significant PKC-independent effect of PMA on mucin secretion. A prime alternate phorbol esterreceptor candidate is the C1-domain protein MUNC13. RT-PCR revealed the expression of ubiquitous (ub)MUNC13-2 and its binding partner, DOC2-␥. Hence, P2Y2 agonists activate nPKC␦ in SPOC1 cells. PMA activates cPKC␣ and nPKC␦ at high affinity and stimulates a lower affinity PKCindependent pathway that leads to mucin secretion. exocytosis; mucus; airways; P2Y receptor THE INVOLVEMENT OF PKC in signal transduction has long been accepted (59), and recent work on the identification of specific PKC isoforms and the determination of their structure and regulation (32, 54, 58) has illuminated many details of this participation. Briefly, PKC is a family of 10 serine/threonine kinase isoforms divided into three subfamilies plus one unique isoform, PKC or PKD, that is included only by virtue of sharing similar catalytic domains. All isoforms except PKC possess a C1 domain, which is a cysteine-rich region of ϳ50 amino acids that in most isoforms is present as a tandem repeat and functions to bind the kinase to phospholipid membranes via diacylglycerol (DAG). C1 domains also bind phorbol esters such as PMA at very high affinity. Conventional PKC isoforms (cPKC␣, -␤I, -␤II, and -␥) possess a double C1 domain that is followed on the COOH-terminal side by a C2, Ca 2ϩ -dependent phospholipid-binding domain. Novel PKC isoforms (nPKC␦, -⑀, -, and -) possess a double C1 domain and a Ca 2ϩ -independent C2 domain on the NH 2 -terminal side of the C1 domain. For novel PKC isoforms, being bound to membranes by DAG or PMA is sufficient for activation. Atypical PKC isoforms [aPKC and -/ (human and rodent, respectively)] possess a single atypical C1 domain and are insensitive to DAG and Ca 2ϩ . These isoforms are activated by phosphoinositide-dependent kinase-1 (PDK-1; Ref. 58). Despite decades of work on the molecular mechanisms of PKC activation and action, there remain significant deficits in our knowledge of PKC function regarding the specific roles in cell regulation played by the various PKC isoforms. The number of agonist-mediated events for which the participating PKC isoforms has been identified rigorously is too small to formulate generalizations. For agonist-regulated exocytotic secretion, for instance, only in GH4 (4) and rat basophilic leukemia (RBL) cells (11) have specific PKC isoforms been identified as having a direct role in the secretory response to agonist, namely, nPKC⑀ and cPKC␤I, respectively.
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Goblet cells in the superficial epithelium of the airways (15) and mucous cells in the submucosal glands (23) are secretory epithelial cells that exocytotically release mucin, which is a polymeric high-molecularweight glycoconjugate that forms the mucus gel responsible for mucociliary clearance. In airway obstructive diseases, arachidonic acid metabolites, inflammatory mediators, bacterial byproducts, reactive oxygennitrogen species, and other agents cause mucin hypersecretion by stimulation of goblet cell and submucosal gland meta-and/or hyperplasia. The stimulation from these sources to secrete mucin in both health and disease appears to be controlled by other agents that emanate from the peripheral nervous system or from cells that effect control through local mediators. For mucous cells in submucosal glands, a vast array of agonists and mediators stimulate mucin secretion; in contrast, goblet cells respond to few signaling agents (18) . Indeed, the only agents shown rigorously to stimulate goblet cells to secrete mucin consistently and across species and experimental models are ATP and UTP, which appear to act via luminal P2Y 2 purinoceptors (P2Y 2 -R; Refs. 2, 16, 40) .
In accord with the general notion that P2Y 2 -R couples through Gq to phospholipase C (26) , inositol phosphate production is elevated in goblet cells by purinergic agonists (40, 41) , and mucin secretion is stimulated by both the DAG mimic PMA and the Ca 2ϩ ionophore ionomycin (16, 17) . Additionally, membrane-associated PKC activity is enhanced by P2Y 2 agonists in SPOC1 cells, and the actions of ionomycin and PMA are fully additive at maximal concentrations, which suggests that Ca 2ϩ and PKC are potentially independent in their actions to effect mucin secretion (1) . In agreement with this notion of independence, we recently reported for permeabilized SPOC1 cells that mucin secretion was activated by PMA when Ca 2ϩ activity was buffered to 10 nM, which is a level well below normal resting levels of intracellular Ca 2ϩ (70) . Hence, the cumulative data support the participation of one or more Ca 2ϩ -independent novel PKC isoforms in the mucin secretory response to purinergic agonist. In this article, RT-PCR/restriction-enzyme mapping and Western blotting techniques were used to identify the PKC isoforms expressed in SPOC1 cells and those that respond uniquely to secretagogue activation of mucin secretion. Additionally, we identified proteins in SPOC1 cells other than PKC that potentially participate in PMAstimulated mucin secretion by virtue of their DAGinteracting C1 domains (36) .
MATERIALS AND METHODS

Materials
Culture medium was purchased from GIBCO-BRL (Gaithersburg, MD), and its supplements were from Collaborative Research (Bedford, MA); nucleotides were purchased from Boehringer-Mannheim (Indianapolis, IN). PKC isoform-specific polyclonal antibodies generated against synthetic peptides corresponding to unique COOH-terminal sequences and the corresponding synthetic peptides were purchased from Santa Cruz Biotechnology (Santa Cruz, CA), Promega (Madison, WI), Life Technologies (Gaithersburg, MD), PanVera (Madison, WI), and Oxford Biomedical Research (Oxford, MI). All other chemicals were purchased from Sigma Chemical (St. Louis, MO).
SPOC1 Cell Culture and Mucin Assay
SPOC1 cells (65) , passages 7-14, were seeded at 9 ϫ 10 3 cells/cm 2 in 100-or 60-mm tissue-culture plates, or in sixwell cluster plates (Costar, Cambridge, MA) and were grown in a DMEM/F-12-based fully defined culture medium (34, 65) . Except for cells that were grown solely for passaging, the medium contained 10 nM retinoic acid. Culture media were changed daily, and the cultures were used for experiments after differentiation of a mucin-secreting phenotype at 14-21 days postconfluence.
Media samples were assessed for mucin content by enzyme-linked lectin assay as described previously (2) . Briefly, 100-l samples were added to the wells of 96-well highbinding microtiter plates (Costar no. 3590) with incubation either overnight at 4°C or for 2 h at 37°C. The unbound materials were removed by washing the plates with PBS that contained 0.05% Tween 20 and 0.02% Thimerosol, and the plates were then incubated with 1-5 g/ml horseradish peroxidase-conjugated soybean agglutinin (SBA) for 1 h at 37°C. After the plates were washed and developed by incubation in 0.04% wt/vol of the substrate (O-phenylene diamine in 0.0175 M citrate-phosphate buffer, pH 5.0, that contained 0.01% hydrogen peroxide), the reaction was stopped by the addition of 4 M sulfuric acid and the optical density was determined at 490 nm (model MR5000 microtiter plate reader, Dynatech, Chantilly, VA). Optical density was converted to nanograms of mucin from standard curves using purified SPOC1 mucin applied to each microtiter plate (2) .
RT-PCR and Restriction-Enzyme Mapping
Total RNA was isolated from SPOC1 cells using TRI reagent (Sigma) in accordance with manufacturer's procedures. In each such preparation used, rRNA bands that resulted from electrophoresis on agarose gels were intact, clearly identifiable, and correctly sized. First-strand cDNA was synthesized from 8 g of total RNA using the SuperScript preamplification system (GIBCO) with oligo-dT as a primer. The subsequent PCR reactions used Taq polymerase (GIBCO) and PKC, the mammalian homolog of the uncoordinated (UNC) Caenorhabditis elegans mutants, MUNC13, or double-C2 (DOC2)-specific primers that were synthesized by the University of North Carolina Department of Pathology Nucleotide Synthesis Facility. Sequence data were analyzed with Genetics Computer Group (GCG, Madison, WI) or Vector-NTI (InforMax, Bethesda, MD) software.
For the PKC isoforms, the forward and reverse primers targeted conserved sequences at the 5Ј end of the C3 domain and in the middle of the C4 domain, respectively. The forward and reverse primers used for conventional and novel isoforms were AARGGSAGYTTTGGSAAG and GGRG-CAAKASTCWGG; for atypical PKC isoforms, they were GGAAGTTATGCCAARGTMCT and GCCATCATCTCAAA-CATRAG. For each PKC isoform, the predicted sizes of the PCR products to result from the use of these primers are indicated in Table 1 .
After separation by electrophoresis in 2% agarose gels, PCR products were stained with ethidium bromide for analysis. Restriction maps of PKC isoform sequences retrieved from GenBank were used to select combinations of restriction enzymes that would cleave the PKC isoform cDNA fragments uniquely within each subfamily (Table 1) . Because the SPOC1 cells were derived from rat trachea, rat PKC isoform sequences were used when available; where necessary, we used sequences from the homologous mouse or human genes. Each analysis, i.e., a PCR plus its associated restrictionenzyme digestion series for a specific PKC subfamily, was conducted at least twice. In two instances, ambiguities in the results warranted additional steps. For an isoform that proved to be nPKC⑀, RT-PCR was used with the common forward primer specified for the conventional and novel PKC isoforms along with the isoform-specific reverse primer CAT-GAGGGCCGATGTGACCT. The resulting PCR product was cloned using a TA Cloning Kit (Invitrogen) and sequenced (Univ. of North Carolina Automated DNA Sequencing Facility). And for an isoform that proved to be aPKC/, the original PCR products were cloned and the nucleotide base sequences were determined. As controls, we used rat brain RNA and PTB vectors that contained rat cPKC␣, nPKC␦, and aPKC, which were kindly provided by Dr. Yoshitaka Ono of the University of Kobe.
The isoforms of MUNC13 expressed in SPOC1 cells were identified in two steps. First, using primers to conserved sequences in the C1 and C2 domains (see Fig. 5 ), we tested for mRNA expression of MUNC13-1, -2, and -3 using the forward and reverse primers CCCACCTACTGCTAYGAGT-GYGA and TGTATWGGGTCACTGGAYCCTGT, respectively. As for PKC isoforms, the PCR fragments were incubated with restriction enzymes selected for their predicted ability to cleave the possible cDNA fragments uniquely: DraIII for MUNC13-1, MscI for MUNC13-2, and RsaI for MUNC13-3. Second, specific primers were used to distinguish between the alternatively spliced mRNAs of MUNC13-2 and to test for MUNC13-4 expression. The MUNC13-2 common forward primer was TGCACGAGAT-GGGGTAGATTAA, and the specific reverse primers for the brain and ubiquitous spliceoforms were AACTCACCTCTTA-CAAACTCA and CTCCGTCAGACCTGATGCTGCA, respectively. For MUNC13-4, the forward and reverse primers were ACCATCCTCTTTCTCCACGCCA and TGAGGAGGGACTG-CAGCCTGGA, respectively. DOC2 mRNA expression in SPOC1 cells was determined using the following isoform-specific forward and reverse primers, respectively: for ␣, TATGATCAGGCTTCCTGCAT and AGCGCCGCAGACATTGAAGA; for ␤, ACTGCACCAT-CAGCAAAGCC and ATAGTCCCAGACAGTGACCTCC; and for ␥, CTGTCCCTGTGCTACAGTTC and CTGCACCCCAC-CAATGAAATC.
To verify the identity of MUNC13 and DOC2 isoforms indicated by positive RT/PCR-restriction-enzyme digestion results, the products were cloned and sequenced as described for PKC isoforms.
Western Blotting
The expression of PKC proteins was determined by Western blotting in SPOC1 cells. Whole cell lysates were prepared and protein concentrations were estimated as previously described (1) . Briefly, after cultures were washed and equilibrated, they were incubated for 40 min or for other time periods as stated (see RESULTS, control conditions or with addition of ATP␥S or PMA at the concentrations indicated). At the end of the incubation period, a sample of the medium was removed for mucin analysis when appropriate to the experiment, and the cells were quickly washed with ice-cold PBS after which they were lysed on ice using a hypotonic buffer (in mM: 20 Tris ⅐ HCl, 2 EGTA, 2 EDTA, 6 ␤-mercaptoethanol, and 0.1 PMSF). At 4°C, the lysed cells were homogenized (15 strokes, Potter-Elvehjem tissue grinder), the extract was centrifuged for 1 h at 100,000 g, and the supernatant was taken as the cytosol fraction. The pellet was solubilized in buffer supplemented with 0.1% Triton X-100, incubated 30-60 min, and centrifuged (14,000 rpm, Eppendorf 5415C microcentrifuge), and the supernatant was taken as the membrane fraction. Samples of the two fractions were taken for protein analysis (BCA Protein Assay Kit, Pierce Biotechnology, Rockford, IL), and the remainder were frozen and stored at Ϫ70°C. Digestion products in bold were positively detected, which indicates expression of the isoform in SPOC1 cells. Sizes predicted were taken from the sequences of rat PKC isoform genes if known. When rat PKC isoform gene sequences were not available, mouse or human genes were used. * Homologous gene: isoform detected in trace amounts by RT-PCR using sequence-specific primers. † Homologous gene: isoform detercted by cloning and sequencing PCR product; sequence showed it to be missing the MseI restriction site.
Within 48 h of the experiment, the cell fractions were thawed, and equivalent amounts of protein (10-20 g/lane) were resolved by 10% SDS-PAGE and electrophoretically transferred to polyvinylidene difluoride membranes. In many experiments, the lysates were first fractionated into cytosol and membrane pools of protein by centrifugation (100,000 g) as described. The blots were probed with PKC isoform-specific antibodies from commercial sources ( Table 2) using dilutions appropriate to the respective analysis. Where possible, antibody specificity was tested by preabsorbing the antibody with the synthetic peptide antigen (50-fold excess). Immunoreactive proteins were detected using enhanced chemiluminescence (Amersham, Arlington Heights, IL). Films of the Western blots were imaged with a platform scanner at a resolution of 600 ϫ 600 dpi and quantitated using MetaMorph image-processing software (Universal Imaging, Downingtown, PA).
RESULTS
SPOC1 cell PKC isoform expression was studied with a dual approach. From total RNA, we used a combination of RT-PCR and restriction-enzyme mapping to first identify the PKC isoform mRNAs that were expressed. Second, using Western blotting with PKC isoform-specific antibodies, we verified the expression at the protein level of those isoforms identified at the mRNA level. Western blotting was also used subsequently to determine which PKC isoforms responded to purinergic stimulation by translocation to the membrane fraction.
Identification of SPOC1 Cell PKC Isoform mRNAs
From oligo-dT primed SPOC1 cell cDNA, the genes that represent PKC isoforms within each subfamily (conventional, novel, and atypical; see Ref. 54 ) were amplified by PCR using degenerate primers that were Ն94% identical to the nucleotide sequences of the known subfamily members. The products of each PCR were digested by restriction enzymes that were selected to cleave specific PKC isoforms based on published nucleotide sequences (see Table 1 ).
Conventional and novel PKC isoforms. The PCR reaction that resulted from primers designed for conventional and novel PKC isoforms from SPOC1 cDNA yielded a single prominent band on an agarose gel with a size ϳ480 bp. The presence of cPKC␣ and cPKC␥ in this band was indicated by the production of fragments of appropriate size produced by following digestion with ApoI, MseI, and NcoI (see Table 1 ) and a diminution in signal strength of the original PCR band at ϳ480 bp (data not shown). By comparison with the band intensity of products judged to represent cPKC␣, those representing cPKC␥ were very weak; hence, the abundance of cPKC␥ in the SPOC1 cell total RNA may be low, or this isoform may have been amplified with low efficiency. SPOC1 cell cDNA did not contain either of the cPKC␤ isoforms as is indicated by the failure of NcoI and PstI to generate digestion products of any size.
The presence of nPKC␦ and nPKC in SPOC1 cell cDNA was indicated by the generation of appropriately sized fragments (see Table 1 ) after digestion of the PCR products by NcoI and PstI (nPKC␦) and by BamHI and PstI (nPKC); NPKC was not expressed. The data relevant to nPKC⑀, however, were equivocal: a very faint band of appropriate size was apparent from a digestion with Xba (data not shown), but appropriately sized bands in the Mse digestion were not apparent (see Table 1 ). To resolve this issue, primers specific to nPKC⑀ were generated. The resulting RT-PCR resulted in a faint band of the proper size on the agarose gel, and the product, after it was cloned, proved to possess the proper sequence for the isoform.
Atypical PKC isoforms. PCR primers for isoforms in the atypical PKC subfamily generated a single, prominent band that is consistent with the predicted size of 557 bp. We identified aPKC by the digestion of a portion of this PCR product by MseI with the generation of appropriately sized fragments (see Table 1 ). Digestion with MseI also generated a product pair of ϳ460 and 100 bp that was inconsistent with any of the known PKC isoforms. Hence, we suspected the existence of an undescribed isoform or, because the rat sequence for aPKC isoform is unknown, that rat aPKC might lack the MseI restriction site that is present in the mouse sequence. To resolve this issue, the aPKC PCR product was cloned, and the nucleotide sequence of four clones was determined. Three of the SPOC1 cell (rat) clones possessed sequences 94% identical with mouse aPKC/, which lacked one of the MseI restriction sites that is found in the mouse sequence. Because of the high degree of identity, we conclude that the gene that yields this clone is the rat homolog of aPKC/. The fourth clone yielded a sequence consistent with aPKC. 
ϩ, positive band on Western blot or its successful disappearance in presence of absorbing synthetic peptide; Ϫ, no band or no competitive absorption; blank, not determined. Vendors: LT, Life Technology; OB, Oxford Biological; P, Promega; PV, Pan Ver; SCB, Santa Cruz Biotechnology.
In summary, analysis of SPOC1 mRNA using a combination of PCR and restriction-enzyme digestion indicated the expression of cPKC␣ and -␥ (trace), nPKC␦, -⑀ (trace), and -, and aPKC and -/.
Western Blot Analysis of SPOC1 Cell PKC Isoform Expression
PKC isoforms were judged to be expressed at the protein level in SPOC1 cells when the appropriate positive signals were present on Western blots (generally when antibodies from two or more independent vendors were used). Rat brain extract was used as a positive control for most isoforms, and specificity was tested with most antibodies by preabsorption with a 50-fold excess by weight of the synthetic peptide antigen. The experiments are summarized in Table 2 .
Conventional PKC isoforms. We found that cPKC␣ appeared to be the only member of the conventional PKC subfamily that was expressed significantly at the protein level in SPOC1 cells (see Table 2 ). Similar probes of SPOC1 cell extracts with antibodies to cPKC␤ ( Fig. 1) and to cPKC␥ were negative, whereas positive signals in both cases were obtained from rat brain. Hence, SPOC1 cells do not appear to express significant amounts of cPKC␤ or -␥, even though for the latter isoform, we detected trace amounts of cPKC␥ mRNA by PCR (see Atypical PKC isoforms in Identification of SPOC1 Cell PKC Isoform mRNAs and Table 1) .
Novel PKC isoforms. We found that nPKC␦ andwere positively identified in extracts of SPOC1 cell and rat brain (see Table 2 ). Like cPKC␥, antibodies against nPKC⑀ tested against SPOC1 cell extracts yielded negative results, whereas faint signals were observed via RT-PCR, and a positive nPKC⑀ signal was obtained by Western blotting from rat brain extracts when the same antibody was used (see Fig. 1 ).
Atypical PKC isoforms. As shown (see Table 2 ), aPKC and -/ were positively identified in extracts of SPOC1 cells.
In summary, Western blotting analysis confirmed the strong signals observed by RT-PCR/restriction-enzyme mapping, which suggests that SPOC1 cells expressed cPKC␣, nPKC␦ and -, and aPKC and -/ at the protein level. However, cPKC␥ and nPKC⑀, for which potentially weak expression was indicated by RT-PCR, were not detected by Western blotting. We also found that cPKC␤, which was not detected by RT-PCR, was similarly undetectable by Western blotting.
Response of SPOC1 Cell PKC Isoforms to Secretagogues.
Conventional and novel PKC isoforms typically translocate from the cytosol to a membrane surface upon activation by DAG or PMA (32, 58) . Hence, as an initial test of the involvement of PKC isoforms in the mucin secretory response of SPOC1 cells, we probed cytosol and membrane fractions of SPOC1 cell extracts by Western blotting using isoform-specific PKC antibodies before and after 40 min of stimulation with PMA (300 nM) and the purinergic agonist ATP␥S (100 M), secretagogue concentrations of which elicit maximal mucin secretory responses from SPOC1 cells (1, 2) . [ATP␥S was used as a P2Y 2 -R agonist to minimize potential extracellular metabolism of the nucleotide; it is equipotent with ATP and UTP in stimulating SPOC1 cell mucin secretion (2) .] The immunoblots for nPKC, aPKC, and aPKC/ indicated that neither PMA nor ATP␥S had effects on their respective distributions between cytosol and membrane fractions (data not shown). In contrast, immunoblots for cPKC␣ indicated a translocation to the membrane fraction induced by PMA; for nPKC␦, both PMA and ATP␥S induced a cytosol-to-membrane translocation. Hence, we evaluated the time courses of the secretagogue-induced translocation of these two isoforms.
The time courses of the individual responses of cPKC␣ and nPKC␦ to PMA are depicted in Fig. 2 . For both isoforms, a significant translocation of PKC from the cytosol to the membrane fraction occurred within the first 15 min of the PMA challenge. The peak translocation of cPKC␣ (approximately a threefold increase) occurred at 30 min, after which the amount of protein in the membrane declined. At 4 h, the amount of cPKC␣ in the membrane exceeded control levels, but the signal at 16 h approximated the control. The relative amounts of nPKC␦ in the membrane fraction, in contrast, were relatively constant at ϳ1.75-fold above the control from 15 to 60 min after PMA addition. Subsequently, the amounts declined sharply: at 4 h after PMA addition, Ͻ25% of the control levels of nPKC␦ remained in the membrane fractions, and undetectable amounts were present at 16 h.
ATP␥S caused a different pattern of translocation responses (Fig. 3 ) from PMA. There was no elevation of cPKC␣ in the membrane fraction in response to ATP␥S: the relative amounts of cPKC␣ in the cytosol and membrane fractions were essentially unchanged from control over the entire 16-h period of the experiment. The relative amounts of nPKC␦ in the membrane fraction, however, were elevated in response to ATP␥S with a peak of ϳ1.75-fold over the control occurring at 30 min. Correspondingly, the amounts of nPKC␦ in the cytosol fraction were diminished by ATP␥S over time; the minimum, ϳ0.4-fold of the control, also occurred 30 min after the agonist challenge. Finally, and in contrast to the longer-term effects of PMA to downregulate nPKC␦ to negligible levels (see Fig. 2 ), the amount of nPKC␦ in the membrane and cytosol fractions returned approximately to control levels following the peak response to ATP␥S (Fig. 3) .
Relationships between Secretagogue-Induced PKC Translocation and Mucin Secretion
The observation that nPKC␦ but not cPKC␣ translocated to the membrane fraction after purinergic stimulation suggests that this isoform may be involved selectively in regulation of the SPOC1 cell mucin secretory responses to agonist. As a more direct test of the causal relationships between nPKC␦ and mucin secretion, we determined the concentration-effect relationships for both PMA and ATP␥S on the translocations of cPKC␣ and nPKC␦ to the membrane fraction and compared these results with the respective concentration-effect relations on mucin release in the same set of SPOC1 cell cultures. The concentration-effect relationships for ATP␥S on cPKC␣ and nPKC␦ translocation and mucin secretion are depicted in Fig. 4A . Consistent with the time-course experiments, ATP␥S had no effect on the distribution of cPKC␣ in the membrane. The relative amount of nPKC␦ in the membrane fraction, however, increased with increasing ATP␥S with a maximal translocation, 1.7 Ϯ 0.1-fold over the control, occurring with 100 M ATP␥S. Interestingly, the effects of ATP␥S on mucin release (Fig.  4A, dashed line) closely paralleled the effects of agonist on membrane-associated nPKC␦: both maxima occurred at 100 M, and the EC 50 value for each event was ϳ2-3 M. Figure 4B shows that PMA induced the translocation of both cPKC␣ and nPKC␦ to the membrane fraction but only at low concentrations. There was a significant elevation in the amount of each membrane-associated isoform at 10 nM PMA, and they saturated at concentrations Ͼ30 nM, at levels of 3.6 Ϯ 0.8-and 3.2 Ϯ 0.8-fold above control, respectively. The pattern of mucin release in this experiment (Fig. 4B, dashed line) paralleled the translocation of cPKC␣ and nPKC␦ to the membrane fraction at low PMA concentrations but continued to increase at higher concentrations with an apparent saturation in the range of 300-1,000 nM PMA. This responsiveness of mucin release to PMA is consistent with our previous studies, which showed that the peak response occurred at 300 nM PMA (1). However, because mucin secretion increased substantially with PMA concentrations Ͼ30 nM, whereas PKC Fig. 3 . Time course of effects of P2Y2 agonist (100 M ATP␥S) on the distribution of cPKC␣ (A) and nPKC␦ (B) between SPOC1 cell cytosol and membrane fractions. Western blots were prepared and quantified as in Fig. 1 (n ϭ 4) . Images of representative immunoblots are shown (insets); lanes correspond to the time points indicated in the bar graphs. translocation into the membrane fraction saturated at 30 nM, a substantial PKC-independent effect of PMA on mucin secretion in SPOC1 cells is indicated.
MUNC13 and DOC2 Expression in SPOC1 Cells
Proteins with DAG-binding C1 domains other than PKC have been described recently (see Ref. 36) ; consequently, one of these "phorbol ester receptors" is likely to be responsible for the PKC-independent effects of PMA on mucin secretion from SPOC1 cells. Of the C1 domain-containing proteins known, few localize to the secretory pathway (36); of those that do, MUNC13 is an especially attractive candidate because of its plasma membrane localization and obligate participation in regulated exocytosis (6, 10) . Using RT-PCR, we probed for the mRNA expression in SPOC1 cells of MUNC13 and its secretory granule membrane-binding partner DOC2 (20) . From SPOC1 cell total RNA, MUNC13-2 was identified initially on the basis of a positive band of the correct size that resulted from the use of common primers for MUNC13-1, -2, and -3, which was followed by the successful digestion of the PCR product by MscI (Fig. 5A) . From the lack of PCR product digestion by DraIII and RsaI, MUNC13-1 and -3 are apparently not expressed. Isoform-specific primers were used subsequently to test whether the brain or ubiquitous splice variant of MUNC13-2 was expressed (8) as well as for the expression of MUNC13-4 (43) . Positive bands were obtained with RT-PCR primers specific to ub-MUNC13-2 and MUNC4 (Fig. 5B) , an identification that was verified by cloning and sequencing the PCR products. Analysis of DOC2 mRNA expression in SPOC1 cells by RT-PCR using specific primers reveals that of the three known isoforms, only DOC2␥ is expressed in SPOC1 cells (Fig. 6) ; this result was again verified by cloning and sequencing the PCR product.
DISCUSSION
Recent intense efforts to define the molecular basis of the regulated exocytotic pathway in nerve terminals and secretory cells have resulted in the identification of many primary and accessory proteins that participate in the process in both types of cells (31) . The core exocytotic complex is composed of one member of each of the three soluble N-ethylmaleimide-sensitive fusion (NSF)-protein-receptor subfamilies: syntaxin and the 25-kDa soluble NSF attachment protein (SNAP-25) in the plasma membrane and in the granule membrane, the vesicle-associated membrane protein, VAMP, or synaptobrevin. As the membranes approach one another during exocytosis, the twisted helices of these proteins are brought into contact and they subsequently interact to leverage the two membranes together to promote membrane fusion (31) . Obligate accessory proteins to the core complex such as MUNC18 and N-ethyl maleimide-sensitive factor are necessary for membrane fusion and core-complex disassembly, whereas others such as synaptotagmin and MUNC13 play regulatory roles, in this case imparting sensitivities to Ca 2ϩ and DAG, respectively (31, 52) . Agonist regulation of exocytotic secretion is initiated by the activation of intracellular signaling cascades that result ultimately in transient increases in Ca 2ϩ and DAG, which trigger exocytosis; note that these transients may be localized to the vicinity of the exocytotic core complex, and in secretory cell exocytosis, the transients may be unrelated to those occurring in the upstream signaling cascades. For most secretory cells including airway goblet cells, agonist activation of exocytosis is largely ill defined beyond receptor activation of intracellular messenger production. Available evidence from model systems suggest, however, that cortical actin microfilaments play a key negative regulatory role in exocytosis by controlling access to docking sites on the plasma membrane and acting as a barrier to the approach of secretory granules (75, 76) . Two proteins appear to effect this necessary disruption of the microfilamentous barrier (see Refs. 56, 74): myristolated alanine-rich C kinase substrate (MARCKS) protein, which anchors microfilaments into the plasma membrane, releases from the membrane when phos- Fig. 4 . Concentration-effect relationships for ATP␥S (A) and PMA (B) on membrane translocation of cPKC␣ and nPKC␦ and on mucin secretion. For each secretagogue, cells were exposed to the concentrations indicated for 30 min. Samples of the medium were then collected for mucin analysis, the reactions were quenched, and the cells were fractionated as described (see MATERIALS AND METHODS). Amount of PKC isoform in the membrane fraction of SPOC1 cells is expressed relative to control; the Western blots were quantified as described in Fig. 1 (n ϭ 7) . Similarly, mucin secretion is expressed relative to control (SE bars, omitted for clarity, were generally Յ 10% of the mean for each point).
phorylated by PKC (27) , and scinderin (or adseverin), a microfilament-severing enzyme that is closely related to gelsolin, which severs microfilaments when activated by Ca 2ϩ (67, 77) . After cortical microfilament disruption, secretory granules dock at the plasma membrane, prime, and exocytose (52), which are processes that occur in a highly regulated fashion and are possibly independent of agonist-related second messengers.
In SPOC1 cells, the available data from RT-PCR and pharmacological experiments indicate that the effects of ATP and UTP to elicit mucin secretion are mediated by P2Y 2 -R localized to the apical membrane (2), which in turn activate PLC thereby causing inositol 1,4,5-trisphosphate production/Ca 2ϩ mobilization and DAG production and initiating the intracellular signaling cascade (17) that leads to mucin secretion. The goal of this work was to identify the PKC isoform(s) in SPOC1 cells that underlie P2Y 2 -mediated mucin secretion to begin the process of identifying these pathways at the molecular level in an airway goblet cell model.
P2Y 2 -R Signaling and PKC Isoform Expression in SPOC1 Cells
In this first study of PKC isoform expression in an airway goblet cell model, RT-PCR/restriction-enzyme mapping and Western blotting analyses showed that SPOC1 cells express cPKC␣, nPKC␦ and -, and aPKC/ and -(see Tables 1 and 2 ). The cPKC␥ and nPKC⑀ mRNAs were identified as very faint bands on agarose gels, but the corresponding proteins were not detected by Western blotting; consequently, these isoforms do not appear to be expressed at physiologically significant levels in these cells. Because aPKC/ was shown to participate in the formation of tight junctions, it is very likely to be expressed ubiquitously in epithelial cells (30) . The cPKC␣, nPKC␦ and -, and aPKC isoforms are widely expressed in epithelial tissues including lung and its airways, gastrointestinal tract, and kidney (13, 33, 46, 55, (61) (62) (63) . Significantly, cPKC␤ and nPKC⑀, which have been implicated widely in both epithelial function (e.g., 7, 12, 66, 73) and regulation of exocytosis (see next section and Refs. 4, 11), are not detectable in SPOC1 cells by Western blotting (see Fig. 1 ). Although the pattern of PKC isoform expression in SPOC1 cells is consistent with the epithelial nature of the cell type (65), departures from the isoforms active in exocytosis in nonepithelial secretory cell types are apparent that may indicate interesting differences in regulation of the secretory event.
Responses of PKC Isoforms to PMA and Purinergic Agonists
In response to stimulation by 300 nM PMA, a concentration that elicits maximal mucin release from SPOC1 cells (1) , cPKC␣ and nPKC␦ were observed to translocate from the cytosol to membrane fractions (see Fig. 2 ), which is as expected for isoforms in the conventional and novel PKC subfamilies. In contrast, nPKC and aPKC and -/ did not undergo PMA-induced translocation. Also, nPKC is insensitive to PMA in keratinocytes (57) but is activated by cholesterol sulfate (19, 29) . This compound in SPOC1 cells, however, had no effect on the localization of nPKC (data not shown). Because cholesterol sulfate has been shown to activate not only nPKC in keratinocytes but also nPKC⑀ and aPKC (19) , and because nPKC is activated by PMA in other cell types (e.g., see Ref. 38) , the regulation of nPKC may prove to be cell specific.
In contrast to PMA, stimulation of SPOC1 cells by a maximal concentration of purinergic agonist (ATP␥S, 100 M) elicited a translocation of nPKC␦ but not CPKC␣ to the membrane fraction (see Fig. 3) . Notably, the development of nPKC␦ translocation after agonist challenge followed a time course that is typical for the SPOC1 cell mucin secretory response (2), which suggests a temporally linked correlation. A more quantitative relationship between nPKC␦ translocation and mucin secretion was suggested by the concentrationeffect study shown in Fig. 4A . Here we found a clear correlation between agonist and relative quantity of nPKC␦ localized to the membrane fraction; importantly, there was also a parallel rise in mucin secretion. Thus these two purinergically driven cellular events are characterized by similar time courses and EC 50 values of 2-3 M and identical concentration maxima of 100 M, all of which strongly support a cause-effect relationship between the translocation of nPKC␦ and mucin secretion.
Although nPKC␦ has been implicated widely in the regulation of cell growth, differentiation, and apoptosis and tumor development (25) , its potential role in the agonist regulation of differentiated cell function is less well understood. The one role suggested for nPKC␦ in airway columnar epithelial cell function is the activation of the Na-K-2Cl cotransporter (NKCCl), which is a function in the superficial epithelium ascribed to the basolateral membrane of ciliated cells (48, 49) . Interestingly, the most logical site for regulatory actions of nPKC␦ in mucin granule exocytosis from goblet cells is the apical membrane; hence, we speculate that nPKC␦ may localize differentially during activation of the two major columnar cell types of the airway epithelium.
The role of PKC in the regulation of exocytosis has been studied extensively in many secretory cells including mucin-secreting cells of the intestine (21, 28) , lachrymal gland (78) , and airway submucosal gland (45, 71) and surface epithelia (1, 15, 35, 42) . Most of these studies, however, have relied exclusively upon the use of phorbol ester (PMA) to activate PKC, and/or they used putative PKC-specific inhibitors for the identification. As with many other kinase inhibitors, most PKC inhibitors have proven to be nonspecific (e.g., Refs. 14, 72). Also, the use of PMA suffers a dual limitation: not only does it attract conventional and novel isoforms to the membrane indiscriminately (51, 60) , it also similarly activates other proteins that have DAG/phorbol ester-binding C1 domains (see next section and Ref. 36 ). Hence, although PMA and inhibitors may be used to generate useful information about PKC and its role in cellular regulation, their utility in identifying specific isoforms that regulate exocytosis or other functions is highly questionable.
In many secretory cells, specific PKC isoforms have been observed to translocate upon agonist activation (e.g., see Refs. 24, 44, 53, 78) , but the putative causeeffect relationships between PKC isoform translocation and exocytosis have not been tested more directly. In only a couple of secretory cell types have specific PKC isoforms been associated with the regulation of exocytosis, by agonist, using relatively rigorous criteria. The nPKC⑀ isoform has been implicated in the TRH-stimulated prolactin secretory response of GH4 cells, which is an anterior pituitary lactotroph cell model: nPKC⑀ translocated to the membrane fraction and was selectively downregulated by TRH stimulation (39) , and prolactin secretion was selectively enhanced by its overexpression (4). Additionally, MARCKS has been recently identified as the major downstream target of nPKC⑀ phosphorylation in these cells (3) , which is consistent with its postulated role in microfilament disruption (74) . A recent paper proposed a different role for MARCKS in regulated mucin secretion from human airway goblet cells: once liberated to the cytoplasm, MARCKS was suggested to bind to mucin granules to allow microfilaments to attach and guide them to the plasma membrane (47) . Although this hypothesis is intriguing, it is contrary to observations on other secretory cell models (see beginning of DISCUSSION), and therefore requires independent verification as well as testing in other systems. In intact RBL cells, which are a mast cell model, CPKC␣ and -␤ and nPKC␦ and -⑀ were observed to translocate to the membrane fraction upon stimulation by antigen. In permeabilized RBL cells following rundown, however, only the exogenous addition of cPKC␤ or nPKC␦ restored exocytotic secretion (64) , and in intact cells, only the overexpression of cPKC␤I correlated with an enhanced antigen-induced secretory response (11) . It is notable, nonetheless, that three different PKC isoforms, cPKC␤I, nPKC⑀, and now, nPKC␦, have been implicated as having a direct role in regulated exocytosis in the three different secretory cells that are best characterized for PKC involvement. Hence, the PKC isoforms that participate in regulated exocytosis, a function that is highly conserved in eukaryotic cells, appear to be surprisingly diverse.
PKC-Independent Effects of PMA
Evidence that favors PKC-independent effects of PMA in eliciting mucin secretion from SPOC1 cells can be observed, retrospectively, in our previous work. For instance, the PMA concentration-effect relationship for mucin secretion exhibited a high EC 50 value of 75 nM that saturated at ϳ300 nM, whereas PKC activity generally saturates at 10-30 nM PMA or phorbol dibutyrate (37, 44, 50) . Furthermore, typical PKC inhibi-tors had negligible to insubstantial (ϳ50% inhibition) effects on ATP-induced mucin secretion, and we observed a full additivity between PMA and ionomycin on mucin secretion at maximum effective concentrations (1, 70) . Although some of these results such as the lack of responsiveness to "PKC" inhibitors can be at least partially attributed to the activation of a novel isoform by PMA (nPKC␦; see Fig. 2 ), those such as a high PMA EC 50 value are more likely due to non-PKC effects of PMA. As shown in Fig. 4B , cPKC␣ and nPKC␦ both translocate maximally to the membrane fraction of SPOC1 cells at 30 nM PMA. That mucin secretion increases significantly as PMA concentrations increase Ͼ30 nM therefore indicates strongly that PMA has effects on the exocytotic mechanism that are independent of PKC.
In recent years, new C1-domain proteins have been discovered that function as alternative phorbol ester receptors to the conventional and novel isoforms of PKC (e.g., see Refs. 36, 68, 69) . The most likely of these proteins to be responsible for the PKC-independent effects of PMA to promote mucin secretion in SPOC1 cells is MUNC13, the mammalian homolog of UNC-13, which associates with the plasma membrane as an essential accessory protein in the exocytotic apparatus of synaptic terminal and model secretory cell systems (9, 10). MUNC13-1, the brain-specific isoform about which we presently know the most, causes early postnatal death in null mice (6) apparently through a loss of the priming reactions that are necessary for synaptic vesicle exocytosis from glutamatergic and other neurons (5, 52) . In SPOC1 cells, we found two MUNC13 isoforms expressed at the mRNA level (see Fig. 5 ), the ubiquitous splice variant of MUNC13-2, ubMUNC13-2 (8), and MUNC13-4 (43). Although MUNC13-4 localizes primarily to goblet cells in the lung (43) , two reasons suggest that ubMUNC13-2 is the isoform most likely to respond to activation of SPOC1 cells by high concentrations of PMA. First, MUNC13-4 lacks the C1 domain characteristic of the other isoforms, which makes it unlikely to respond to PMA. Second, the NH 2 -terminal region of ubMUNC13-2 is homologous with that of MUNC13-1, a region through which both isoforms bind RIM1 (8) . It is by its interaction with RIM1 that MUNC13-1 is thought to be localized to the exocytotic active zone (52); by analogy, ubMUNC13-2 most likely localizes by the same mechanism.
The DOC2 protein associates with secretory granule membranes and functions as the binding partner for MUNC13 in exocytotic priming reactions (20) . Hence, if MUNC13 is important in regulated mucin secretion from SPOC1 cells, we would expect to also find DOC2 expression. As shown in Fig. 6 , in fact, DOC2␥ (22) is also expressed in SPOC1 cells.
In conclusion, the novel PKC isoform nPKC␦ translocates uniquely to the membrane fraction during P2Y 2 -R-activated mucin secretion from SPOC1 cells. This event correlates well temporally with the onset of mucin secretion and exhibits a saturating concentration-effect relationship with agonist. PMA causes both cPKC␣ and nPKC␦ to translocate in a concentrationdependent fashion that saturates at 30 nM. Mucin secretion continues to increase with increasing PMA concentrations Ͼ30 nM, however, which indicates that a substantial part of the PMA effect is PKC independent. This PKC-independent effect of PMA is likely mediated by ubMUNC13-2 and DOC2␥, both of which are expressed in SPOC1 cells.
NOTE ADDED IN PROOF
In experiments performed since manuscript submission to check the persistent finding of nPKC⑀ mRNA expression in SPOC1 cells, we have now an antibody different from the one used herein (SBC instead of LT; see Table 1 ). This probe yielded a positive band of the correct size for nPKC⑀ in Western blots; hence, the protein, in fact, appears to be expressed in SPOC1 cells. In three experiments, however, nPKC⑀ did not translocate to the membrane from the cytosolic fraction following stimulation of the cells with purinergic agonist, as we report here for nPKC␦. Consequently, nPKC␦ may play a singular role in regulated mucin granule exocytosis.
